Slide 1: Q2 2023 Results Presentation
Q2 2023 Results Presentation Dietmar Siemssen, CEO Dr. Bernd Metzner, CFO Duesseldorf, July 6, 2023
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Strong Q2 2023: Maintaining Profitable Growth Momentum
Strong Q2 2023: Maintaining Profitable Growth Momentum Key Take-Aways Q2 2023: Strong Orderbook Including GLP-1 Projects Double-Digit Growth: Execution on growth Strong growth and projects according margin expansion Revenue growth Adj. EBITDA growth: to plan maintained in Q2 +12.8% (FXN) +21.8% (FXN
Slide 4: Strong Foundation for Further, Sustainable Growth
Strong Foundation for Further, Sustainable Growth Deep Dive Capital Increase: Successful Capital Increase to Unlock Additional Growth Opportunities — Focus on High Value Solutions and Medical Devices, including solutions for biopharmaceuticals, with applications in the field of GLP-1 Capital increas
Slide 5: Reaching the Next Level of Sustainable Value Creation
Reaching the Next Level of Sustainable Value Creation Deep Dive Capital Increase: Indicative Allocation of Funds Focusing on Profitable Growth Drivers Investments in Solutions for GLP-1 applications and further biologics strengthen our unique portfolio to serve our global customers as strategic part
Slide 6: Growth Investments as Key Driver for Margin Expansion
Growth Investments as Key Driver for Margin Expansion Extend Global Footprint to Serve Existing and New Customers Globally Czech Republic USA Denmark Horsovsky Tyn Peachtree | Morganton | Berlin | Haarby | Vaerloese Chicago Heights | Vineland Poland Boleslawiec Germany Bünde | Pfreimd | Wertheim | E
Slide 7: Strategic Partner of Choice for Global Pharma and Biotech Solutions
Strategic Partner of Choice for Global Pharma and Biotech Solutions Digital Containment Eco-System Solutions Digital therapy support Bring the drug to the patient Drug Devices & Delivery Systems Bring the drug into the patient 7 6-July-2023 Gerresheimer AG - Q2 2023 Results Presentation
Slide 8: Double-digit growth in Q2 2023
Double-digit growth in Q2 2023 Dr. Bernd Metzner (CFO)
Slide 9: Another Profitable Double-Digit Growth Quarter
Another Profitable Double-Digit Growth Quarter Operational View on KPIs in Q2 2023: Profitable Growth organic growth Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) 12.8% 21.8% 3.7% 107 500 90 445 1.33 1.30 109 498 90 441 1.34 1.39 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Reporte
Slide 10: Strong Performance With Margin Expansion
Strong Performance With Margin Expansion Q2 2023: Divisional Performance and Highlights Organic yoy & margin1 In EUR m1 Revenues Adj. EBITDA Double-digit organic growth and strong margin expansion +16.7% 265 +33.4% 228 69 ▪ Strong org. growth of 16.7% resulting from higher customer P&D 53 demand acr
Slide 11: Reconciliation Q2 2023: Strong EPS Performance Despite Capital Increase
Reconciliation Q2 2023: Strong EPS Performance Despite Capital Increase Reported and Adjusted Financials Q2 2023 Q2 2022 Org. growth YoY2 Comments 1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 499.6 499.6 444.6 12.8% EBITDA 106.7 0.5 107.2 90.1 21.8% Depreciation & Non-recurring
Slide 12: FCF Performance as Expected
FCF Performance as Expected Free Cash Flow and Net Financial Debt In EUR m1 Q2 2023 Q2 2022 Change Comments Adjusted EBITDA 107.2 90.1 17.1 Earnings significantly increased Change in net working capital -21.0 -50.2 29.2 Net interest paid -9.8 -2.9 -6.9 Euribor increase for variable part of debt Net
Slide 13: Outlook
Outlook Dietmar Siemssen (CEO)
Slide 14: All Aspects of Guidance Maintained as Strong Performance Offsets Increased Share Count
All Aspects of Guidance Maintained as Strong Performance Offsets Increased Share Count FY 2023 and Mid-Term Guidance Group level guidance1 focused on three key drivers of shareholder value Revenue Adjusted EBITDA Adjusted EPS ≥ 10% Low ≥ 10% single-digit (Adj. EBITDA FY 2023 growth growth) growth ≥
Slide 15: Maintain Profitable Growth Momentum
Maintain Profitable Growth Momentum Outlook for the second half 2023: Continuation of Success Story ▪ We are on track to deliver on our guidance H2 ▪ Adjusted EBITDA margin is expected to improve year-on-year 2023 ▪ New orders in biologics expected, also GLP-1 15 6-July-2023 Gerresheimer AG - Q2 202
Slide 16: Appendix
Appendix
Slide 17: Financial Calendar
Financial Calendar Publication 3rd Publication Financial Publication 1st Publication 2nd Quarter Results 2023 Year 2023 Results Quarter Results 2024 Quarter Results 2024 October February April July 5th, 2023 22nd, 2024 11th, 2024 11th, 2024 17 6-July-2023 Gerresheimer AG - Q2 2023 Results Presentati
Slide 18: Q2 Revenue & Organic Growth Reconciliation
Q2 Revenue & Organic Growth Reconciliation (1 of 2) in EUR m1 organic growth +12.8% 497.7 1.9 499.6 -0.2 -0.6 19.6 37.7 +9.2% 444.6 -3.5 441.2 +16.7% Revenue Q2 2022 FX Revenue Q2 P&D PPG GAT HQ, Cons. Revenue Q2 FX Revenue Q2 2023 2022 (FXN) 2023 (FXN) 1. Due to the commercial rounding of figures,
Slide 19: Q2 Adj. EBITDA & Organic Growth Reconciliation
Q2 Adj. EBITDA & Organic Growth Reconciliation (2 of 2) in EUR m1 organic growth & margin +21.8% -2.6 8.0 -3.4 109.4 107.2 -2.2 17.5 90.1 89.9 -0.2 Adj. EBITDA FX Adj. EBITDA P&D PPG GAT HQ, Cons. Adj. EBITDA FX Adj. EBITDA Q2 2022 Q2 2022 (FXN) Q2 2023 (FXN) Q2 2023 1. Due to the commercial roundin
Slide 20: H1 Revenue & Organic Growth Reconciliation
H1 Revenue & Organic Growth Reconciliation (1 of 2) in EUR m1 organic growth +16.6% 6.2 957.4 951.2 0.6 -0.6 59.8 75.6 815.4 815.8 0.4 Revenue H1 2022 FX Revenue H1 P&D PPG GAT HQ, Cons. Revenue H1 FX Revenue H1 2023 2022 (FXN) 2023 (FXN) 1. Due to the commercial rounding of figures, small deviation
Slide 21: H1 Adj. EBITDA & Organic Growth Reconciliation
H1 Adj. EBITDA & Organic Growth Reconciliation (2 of 2) in EUR m1 organic growth & margin +23.1% -2.8 -4.0 188.1 185.2 18.6 -2.9 23.5 151.6 152.8 1.2 Adj. EBITDA FX Adj. EBITDA P&D PPG GAT HQ, Cons. Adj. EBITDA FX Adj. EBITDA H1 2022 H1 2022 (FXN) H1 2023 (FXN) H1 2023 1. Due to the commercial round
Slide 22: Reconciliation H1 2023
Reconciliation H1 2023 Reported and Adjusted Financials H1 2023 H1 2022 Org. growth YoY2 In EUR m1 Reported Adjustment Adjusted Adjusted Adjusted Revenues 957.4 957.4 815.4 16.6% EBITDA 181.4 3.8 185.2 151.6 23.0% Depreciation & Amortization -90.7 19.5 -71.2 -58.0 EBIT 90.7 23.3 114.0 93.5 Financial
Slide 23: Financial Headroom
Financial Headroom Net Financial Debt & Adjusted EBITDA Leverage Net Financial Debt according to credit agreement in force Maturity Profile In EUR m In EUR m 1,087 Net Financial Debt Promissory loans (In EUR m)1 931 Revolving credit facilities (RCF) 3.4 Adj. EBITDA leverage (x) 2.4 May-23 May-22 200
Slide 24: innovating for a better life
innovating for a better life